图卡替尼联合T-DM1治疗经治HER2阳性晚期乳腺癌的III期试验
HER2CLIMB-02研究纳入463例经曲妥珠单抗和紫杉类治疗的HER2阳性局部晚期或转移性乳腺癌患者(含脑转移),随机接受T-DM1联合图卡替尼或安慰剂。中位随访24.4个月,图卡替尼组中位无进展生存期(PFS)为9.5个月,对照组为7.4个月(HR 0.76,95%CI 0.61-0.95,P=0.0163),各预设亚组(含脑转移)均观察到PFS获益;总生存数据尚未成熟。
要点
- 图卡替尼联合T-DM1较T-DM1单药显著改善经治HER2阳性LA/MBC患者的PFS。
- PFS获益在所有预设亚组中一致,包括脑转移患者。
- 联合组≥3级TEAE和因TEAE停药发生率更高,常见≥3级TEAE为转氨酶升高。
核心结论
- 在经治HER2阳性局部晚期或转移性乳腺癌患者(含脑转移)中,T-DM1联合图卡替尼较T-DM1单药改善PFS,安全性可控。
研究设计与样本
- 随机、双盲、安慰剂对照III期HER2CLIMB-02研究(NCT03975647),共随机分配463例患者。
- 入组患者为HER2阳性局部晚期或转移性乳腺癌,既往接受过曲妥珠单抗和紫杉类治疗(任何阶段),包括脑转移患者。
- 患者1:1随机接受T-DM1(3.6 mg/kg静脉每21天)联合图卡替尼(300 mg口服每日两次)或安慰剂(口服每日两次)。
主要发现
- 中位随访24.4个月,图卡替尼组中位PFS为9.5个月,对照组为7.4个月(HR 0.76,95%CI 0.61-0.95,P=0.0163)。
- 所有预设亚组(包括脑转移患者)均观察到PFS获益。
- 总生存中期分析数据未成熟,图卡替尼组中位OS未达到,对照组为38.0个月(HR 1.23,95%CI 0.87-1.74)。
- 图卡替尼组因TEAE导致任何治疗停药的发生率为22.1%,对照组为11.6%;≥3级TEAE发生率分别为68.8%和41.2%。
- 图卡替尼组最常见≥3级TEAE为丙氨酸氨基转移酶升高(16.5%)和天冬氨酸氨基转移酶升高(16.5%),对照组均为2.6%。
关键数值与推荐
- T-DM1剂量为3.6 mg/kg静脉每21天;图卡替尼剂量为300 mg口服每日两次;安慰剂口服每日两次。
- 主要疗效终点PFS:图卡替尼组9.5个月 vs 对照组7.4个月,HR 0.76(95%CI 0.61-0.95),P=0.0163。
- 安全性:因TEAE停药率22.1% vs 11.6%;≥3级TEAE发生率68.8% vs 41.2%。
临床怎么用
- 对于经曲妥珠单抗和紫杉类治疗的HER2阳性局部晚期或转移性乳腺癌患者,可考虑T-DM1联合图卡替尼以改善PFS。
- 联合方案在脑转移患者中亦观察到PFS获益,但需关注转氨酶升高等≥3级TEAE及因毒性停药风险。
局限性
- 总生存数据尚未成熟,需更长随访。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Trastuzumab emtansine (T-DM1) is a standard treatment option in patients with previously treated human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer (LA/MBC). Here, we report the efficacy and safety of tucatinib in combination with T-DM1 compared with T-DM1 alone from the phase III HER2CLIMB-02 study (NCT03975647). PATIENTS AND METHODS: Eligible patients had HER2-positive LA/MBC that had been previously treated with trastuzumab and a taxane in any setting; these included patients with brain metastases (BMs). Patients were randomly assigned 1 : 1 to receive T-DM1 (3.6 mg/kg intravenously every 21 days) combined with either tucatinib (300 mg orally twice daily) in the tucatinib arm or placebo (orally twice daily) in the control arm. RESULTS: In total, 463 patients were randomly assigned. After a median follow-up duration of 24.4 months, the median progression-free survival (PFS) was 9.5 months in the tucatinib arm and 7.4 months in the control arm [hazard ratio (HR) 0.76, 95% confidence interval (CI) 0.61-0.95, P = 0.0163]. A PFS benefit was observed across all prespecified subgroups, including in patients with BMs. Interim overall survival analysis results were immature. The median OS was not reached in the tucatinib arm and was 38.0 months in the control arm (HR 1.23, 95% CI 0.87-1.74). The incidences of treatment-emergent adverse events (TEAEs) associated with any treatment discontinuation and of grade ≥3 TEAEs were higher in the tucatinib arm than in the control arm (22.1% versus 11.6% and 68.8% versus 41.2%, respectively). The most common grade ≥3 TEAEs in the tucatinib arm were elevated alanine aminotransferase (16.5%) and aspartate aminotransferase levels (16.5%) (versus 2.6% for both in the control arm). CONCLUSION: The addition of tucatinib to T-DM1 improved PFS in patients with previously treated HER2-positive LA/MBC, including patients with BMs, and exhibited a manageable safety profile.
引用
- Hurvitz SA, Loi S, O'Shaughnessy J, et al. Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02. Ann Oncol. 2025. PMID: 41260264. doi:10.1016/j.annonc.2025.11.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。